Clinical Trial Update: Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age [Phase 3]

View source ↗

Summary

Sanofi is evaluating a 21-valent pneumococcal conjugate vaccine (PCV21) in healthy infants starting around 2 months of age in a Phase 3 trial that is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PCV21 (Pneumococcal conjugate vaccine, 21-valent)

Snippet

Sponsor: Sanofi | Conditions: Pneumococcal Immunization, Healthy Volunteers | Phase 3 | Status: ACTIVE_NOT_RECRUITING